MeadWestvaco Corporation (MWV) recently received a grant to provide the Bill & Melinda Gates Foundation with its Medication Event Monitoring System (MEMS) for use in a project to help prevent the spread of HIV/AIDS in Africa and India.
The MEMS system tracks whether patients regularly take their pre-exposure of prophylaxis (PrEP) medications.
PrEP medications are currently being given to people who do not have HIV, but are at high risk of contracting it. They have been shown to prevent the spread of HIV/AIDS when regularly taken.
The MEMS system uses MWV's MEMSCap smart electronic medication packaging, which records every time the patient opens the medication bottle. This data is then sent to MedAmigo, a secure Web-based program that analyzes the information.
Previous studies have shown that MEMS tracking has successfully influenced patients to take their medications on a regular basis.
“PrEP medications are transforming the way we approach the global HIV/AIDS battle, offering a promise of protection against this deadly virus,” Bernard Vrijens, chief science officer for MWV Healthcare, said. “However this transformational intervention is only effective when people adhere to the prescribed dosing regimen. MWV Healthcare is grateful for the opportunity to join with the Gates Foundation in this important research helping to understand and increase adherence to these life-changing medications.”